相关实验视频
Updated: Jul 18, 2025

04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
500
肥胖争议:它是否会影响扩散型大B细胞淋巴瘤的治疗反应?
Suheyla Atak1, Stemi Serin2, Naciye Demirel1
1University of Health Sciences, Okmeydanı Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey.
概括
这项研究发现,身体质量指数 (BMI) 在扩散型大B细胞淋巴瘤 (DLBCL) 患者的治疗反应上没有显著的影响. 进一步的研究可能会探索其他影响DLBCL结果的因素.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床研究 临床研究
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种侵略性的非霍奇金淋巴瘤.
- 了解影响治疗反应的因素对于改善患者的治疗结果至关重要.
- 身体质量指数 (BMI) 是一种随时可用的指标,可能与疾病预后相关.
研究的目的:
- 研究DLBCL患者的身体质量指数 (BMI) 和治疗反应之间的关联.
- 确定BMI是否影响DLBCL的关键临床特征和结果.
主要方法:
- 79名DLBCL患者病历的回顾性审查.
- 收集的数据包括年龄,性别,LDH,B症状,IPI得分,ECOG,阶段,节外参与,以及诊断时的BMI.
- 根据世卫组织的BMI分类,患者被分为体重不足,体重正常,超重和肥胖的组.
主要成果:
- 在正常体重,超重和肥胖群体之间进行了比较,因为有限的体重不足患者.
- 在BMI组之间没有观察到年龄,性别,LDH,疾病阶段,B症状,外节参与,ECOG,IPI得分或治疗反应方面的统计学上显著差异.
- 治疗反应和其他因素的P值在0.070到0.947之间,表明与BMI没有显著的关联.
结论:
- 身体质量指数 (BMI) 似乎没有显著影响DLBCL患者的治疗反应.
- 这些发现表明,单独的BMI并不是该患者队列治疗结果的预测因素.
- 可能需要对更大的队列进行进一步的研究,以探索与其他预后因素的潜在微妙关联或相互作用.
相关概念视频
Obesity
534
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
534
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
354
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
354
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
149
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
149
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173

